Document is current

Article History

Received: 5 May 2020

Accepted: 25 January 2021

First Online: 25 February 2021

Competing interests

: A.K. received grants, consulting fees, revenue distribution agreement, speaker fees and travel support with AVROBIO, Inc. as well as revenue distribution agreement with University Health Network regarding gene therapy using technology from this work. D.L.B. and J.H. were partially paid from a Sponsored Research Agreement—AVROBIO, Inc. C. A. Rupar has the following financial relationships to disclose: the Biochemical Genetics clinical diagnostic laboratory at his home institution is contracted by AVROBIO, Inc. to assay enzymes on a fee for service basis. He is the laboratory director but receives no personal compensation. C.A.-B. has received a service contract and honoraria for biomarker analysis with AVROBIO, Inc., grant from CIHR. K.G. had travel paid for by AVROBIO, Inc. S.W. has received nonfinancial support from Sanofi-Genzyme, nonfinancial support from Takeda Pharmaceuticals (formerly Shire HGT), personal fees and nonfinancial support from Amicus Therapeutics. K.L. has received travel grant and honorarium from Amicus Therapies; travel grant and speaker fees from Sanofi-Genzyme; travel grant, consulting fees and speaker fees from Takeda Pharmaceuticals; medical advisor to the Canadian Fabry Disease Association. C.F.M. has received grants, personal fees, and nonfinancial support from Takeda Pharmaceuticals (previously Shire HGT), grants, personal fees and nonfinancial support from Sanofi-Genzyme, nonfinancial support from Amicus Therapeutics. A.K. has received consultancy fees from AVROBIO, Inc. unrelated to this study. M.L.W. has received research grants, consulting fees, speaker fees and travel support with Amicus Therapeutics, Protalix, Sanofi-Genzyme and Takeda, revenue distribution agreement with University Health Network regarding gene therapy using technology from this work. J.A.M. has the following financial relationships to disclose: SAB—Rapa Therapeutics. Honoraria—Sanofi-Genzyme, Shire. Co-Founder—AVROBIO, Inc. Shareholder—AVROBIO, Inc. Grants from Canadian Institutes of Health Research and Kidney Foundation of Canada and AVROBIO, Inc. M.B., A.C., P.R.D., R.F., D.H.F., G.F., S.J., W.M.M., P.O., N.P., and J.W.R. have no financial relationships to disclose in relation to this trial.